3D Bioprinting Market To Witness Enhance Demand In Food & Animal Product Testing, Tissue & Organ Generation, Dental And Medical Sectors Till 2022: Grand View Research, Inc.

Grand View Research, Inc. – Market Research And Consulting.
New Market Research Reports Title Global 3D Bioprinting Market Analysis Size And Segment Forecasts To 2022 Has Been Added to GrandViewReseach.com Report Database

3D bioprinting is the manufacture of biological organs; with cell function & viability preserved. 3D bioprinters use bio-ink; creating a cellular structure layer by layer, finally resulting in a functioning living tissue or organ.

The 3D bioprinting market was estimated at USD 487 million in 2014. It would reach around USD 1.8 billion by 2022. The geriatric population and 3D bioprinting innovations are the major market drivers. As of 2015, research institutes & universities have shown interest in expanding this technology. For instance, the Heriot-Watt University in Scotland has created bioprinters that can print stem cell structures.

Full research report on Global 3D Bioprinting Market Analysis:

On the basis of technologies, the 3D bioprinting market is sliced into magnetic levitation, syringe based, laser based, and inkjet based printing. Magnetic levitation and syringe based printers held a larger share in 2014. Growth of the former can be attributed to toxicity screenings, cell modeling, and smooth muscle printing. The latter finds applications in cell strip printing, tissue printing, and fabricating scaffolds. Laser based would experience the fastest growth in the forecast period.

Applications of the 3D bioprinting market include bioinks, biosensors, medical, pills, implants, prosthetics, food & animal product testing, tissue & organ generation, dental, and medical. Medical is likely to dominate the market, with more than 32% share by 2022. Medical pills would enjoy significant growth on account of demand for medicines. These medicines can be mass-produced using 3D bioprinting.

Request for sample of this research report:

In August 2015, Aprecia Pharmaceuticals was the first company to have received FDA (Food & Drug Administration) approval for 3D printing their drug, ‘Spritam.’ North America captured a share above 35% in 2014. It would lead the market during the forecast period, with over 10% CAGR. This regional market would undergo windfall due to sophisticated medical infrastructure and high disposable incomes.

Asia Pacific will remain lucrative considering its research investments and adoption of healthcare technologies. Players of the worldwide 3D bioprinting market include 3Dynamics Systems, Organovo Holding Inc., Cyfuse Biomedical, Solidscape, and Luxexcel Group BV. They hold exhibitions and seminars to raise public awareness regarding 3D bioprinting. They even collaborate with research institutes to improve their technologies and grow their size.

View more reports of this category by Grand View Research at:

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Web: www.grandviewresearch.com

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
State: California
Country: United States
Website: http://www.grandviewresearch.com/industry-analysis/3d-bioprinting-market